drugset / Trial / NCT07363265
Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, proof-of-concept, phase Ⅱ adaptive basket clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic profile of LP-005 Injection as add-on therapy to standard treatment in patients with complement-mediated renal diseases.
Timeline
- Start
- 2026-02-02
- Primary completion
- 2028-08-02
- Completion
- 2029-05-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LP-005 | Protein / enzyme biologic | 1200 mg | Intravenous |
| Subject | LP-005 | Protein / enzyme biologic | 1500 mg | Intravenous |
Indications
No indication recorded.